Search

Your search keyword '"SPADARO, Giuseppe"' showing total 356 results
Start Over Author "SPADARO, Giuseppe" Search Limiters Available in Library Collection
356 results on '"SPADARO, Giuseppe"'

1. Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI)

Author

Calabrese, Cecilia, Camiciottoli, Gianna, Carpagnano, Giovanna Elisiana, Centanni, Stefano, Corsico, Angelo Guido, Costantino, Maria Teresa, Crimi, Claudia, D'Adda, Alice, D’Alò, Simona, D'Amato, Maria, D'Andria, Corrado, Del Giacco, Stefano, Di Marco, Fabiano, Facciolongo, Nicola Cosimo, Farsi, Alessandro, Latorre, Manuela, Milanese, Manlio, Nettis, Eustachio, Nucera, Eleonora, Passalacqua, Giovanni, Pelaia, Girolamo, Pini, Laura, Ricciardi, Luisa, Massimo Ricciardolo, Fabio Luigi, Richeldi, Luca, Ridolo, Erminia, Santus, Pierachille, Scichilone, Nicola, Senna, Gianenrico, Spadaro, Giuseppe, Spanevello, Antonio, Tarsia, Paolo, Canonica, Giorgio Walter, Blasi, Francesco, Paggiaro, Pierluigi, Heffler, Enrico, Braido, Fulvio, Brussino, Luisa, Scioscia, Giulia, Cardini, Cristina, Oriecuia, Chiara, Sala, Isabella, and Bagnardi, Vincenzo

Published
2025
Full Text
View/download PDF

2. The dilemma of X-linked agammaglobulinemia carriers

Author

Pulvirenti, Federica, Milito, Cinzia, Cinetto, Francesco, Garzi, Giulia, Sardella, Germano, Spadaro, Giuseppe, Lippi, Francesca, Guarnieri, Valentina, Cinicola, Bianca Laura, Carrabba, Maria, Guadagnolo, Daniele, Fabio, Giovanna, Martire, Baldassarre, Cancrini, Caterina, Lanzoni, Giulia, Finocchi, Andrea, Di Matteo, Gigliola, Pompilii, Eva, Ferrari, Simona, and Quinti, Isabella

Published
2025
Full Text
View/download PDF

3. Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort

Author

Brussino, Luisa, Calabrese, Cecilia, Camiciottoli, Gianna, Carpagnano, Giovanna E., Centanni, Stefano, Corsico, Angelo G., Costantino, Maria T., Crimi, Claudia, D'adda, Alice, D'alo, Simona, D'amato, Maria, Del Giacco, Stefano, Di Marco, Fabiano, Facciolongo, Nicola C., Latorre, Manuela, Nettis, Eustachio, Nucera, Eleonora, Passalacqua, Giovanni, Pelaia, Girolamo, Pini, Laura, Ricciardi, Luisa, Richeldi, Luca, Ridolo, Erminia, Santus, Pierachille, Scichilone, Nicola, Scioscia, Giulia, Spadaro, Giuseppe, Spanevello, Antonio, Tarsia, Paolo, Caminati, Marco, Marcon, Alessandro, Vaia, Rachele, Senna, Gianenrico, Maule, Matteo, Marchetti, Pierpaolo, Miotti, Jessica, Argentino, Giuseppe, Blasi, Francesco, Canonica, Giorgio W., Heffler, Enrico M., Paggiaro, Pierluigi, Vianello, Andrea, and Guarnieri, Gabriella

Published
2024
Full Text
View/download PDF

6. Coronavirus disease 2019 in patients with inborn errors of immunity: An international study

Author

Meyts, Isabelle, Bucciol, Giorgia, Quinti, Isabella, Neven, Bénédicte, Fischer, Alain, Seoane, Elena, Lopez-Granados, Eduardo, Gianelli, Carla, Robles-Marhuenda, Angel, Jeandel, Pierre-Yves, Paillard, Catherine, Sankaran, Vijay G, Demirdag, Yesim Yilmaz, Lougaris, Vassilios, Aiuti, Alessandro, Plebani, Alessandro, Milito, Cinzia, Dalm, Virgil ASH, Guevara-Hoyer, Kissy, Sánchez-Ramón, Silvia, Bezrodnik, Liliana, Barzaghi, Federica, Gonzalez-Granado, Luis Ignacio, Hayman, Grant R, Uzel, Gulbu, Mendonça, Leonardo Oliveira, Agostini, Carlo, Spadaro, Giuseppe, Badolato, Raffaele, Soresina, Annarosa, Vermeulen, François, Bosteels, Cedric, Lambrecht, Bart N, Keller, Michael, Mustillo, Peter J, Abraham, Roshini S, Gupta, Sudhir, Ozen, Ahmet, Karakoc-Aydiner, Elif, Baris, Safa, Freeman, Alexandra F, Yamazaki-Nakashimada, Marco, Scheffler-Mendoza, Selma, Espinosa-Padilla, Sara, Gennery, Andrew R, Jolles, Stephen, Espinosa, Yazmin, Poli, M Cecilia, Fieschi, Claire, Hauck, Fabian, Cunningham-Rundles, Charlotte, Mahlaoui, Nizar, Errors of Immunity, IUIS Committee of Inborn, Warnatz, Klaus, Sullivan, Kathleen E, and Tangye, Stuart G

Subjects
Vaccine Related, Clinical Research, Pneumonia & Influenza, Prevention, Pediatric, Emerging Infectious Diseases, Pneumonia, Infectious Diseases, Lung, Biodefense, Rare Diseases, Good Health and Well Being, Adolescent, Adult, Aged, COVID-19, Child, Child, Preschool, Female, Genetic Diseases, Inborn, Humans, Immunologic Deficiency Syndromes, Infant, Infant, Newborn, Male, Middle Aged, Retrospective Studies, Risk Factors, SARS-CoV-2, Severity of Illness Index, Young Adult, primary immunodeficiencies, inborn errors of immunity, hypogammaglobulinemia, immune dysregulation, IUIS Committee of Inborn Errors of Immunity, Immunology, Allergy
Abstract

BackgroundThere is uncertainty about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in individuals with rare inborn errors of immunity (IEI), a population at risk of developing severe coronavirus disease 2019. This is relevant not only for these patients but also for the general population, because studies of IEIs can unveil key requirements for host defense.ObjectiveWe sought to describe the presentation, manifestations, and outcome of SARS-CoV-2 infection in IEI to inform physicians and enhance understanding of host defense against SARS-CoV-2.MethodsAn invitation to participate in a retrospective study was distributed globally to scientific, medical, and patient societies involved in the care and advocacy for patients with IEI.ResultsWe gathered information on 94 patients with IEI with SARS-CoV-2 infection. Their median age was 25 to 34 years. Fifty-three patients (56%) suffered from primary antibody deficiency, 9 (9.6%) had immune dysregulation syndrome, 6 (6.4%) a phagocyte defect, 7 (7.4%) an autoinflammatory disorder, 14 (15%) a combined immunodeficiency, 3 (3%) an innate immune defect, and 2 (2%) bone marrow failure. Ten were asymptomatic, 25 were treated as outpatients, 28 required admission without intensive care or ventilation, 13 required noninvasive ventilation or oxygen administration, 18 were admitted to intensive care units, 12 required invasive ventilation, and 3 required extracorporeal membrane oxygenation. Nine patients (7 adults and 2 children) died.ConclusionsThis study demonstrates that (1) more than 30% of patients with IEI had mild coronavirus disease 2019 (COVID-19) and (2) risk factors predisposing to severe disease/mortality in the general population also seemed to affect patients with IEI, including more younger patients. Further studies will identify pathways that are associated with increased risk of severe disease and are nonredundant or redundant for protection against SARS-CoV-2.

Published
2021

10. Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life

Author

Nettis, Eustachio, Brussino, Luisa, Patella, Vincenzo, Bonzano, Laura, Detoraki, Aikaterini, Di Leo, Elisabetta, Sirufo, Maria Maddalena, Caruso, Cristiano, Lodi Rizzini, Fabio, Conte, Mariaelisabetta, Yacoub, Mona-Rita, Triggiani, Massimo, Ridolo, Erminia, Macchia, Luigi, Rolla, Giovanni, Brancaccio, Raffaele, De Paulis, Amato, Spadaro, Giuseppe, Di Bona, Danilo, D’Uggento, Angela Maria, Ginaldi, Lia, Gaeta, Francesco, Nucera, Eleonora, Jaubashi, Kliljeda, Villalta, Danilo, Dagna, Lorenzo, Ciotta, Domenico, Pucciarini, Francesco, Bagnasco, Diego, Celi, Giorgio, Chieco Bianchi, Fulvia, Cosmi, Lorenzo, Costantino, Maria Teresa, Crivellaro, Maria Angiola, D’Alò, Simona, del Biondo, Pietro, Del Giacco, Stefano, Di Gioacchino, Mario, Di Pietro, Linda, Favero, Elisabetta, Gangemi, Sebastiano, Guarnieri, Gabriella, Heffler, Enrico, Leto Barone, Maria Stefania, Lombardo, Carla, Losa, Francesca, Matucci, Andrea, Minciullo, Paola Lucia, Parronchi, Paola, Passalacqua, Giovanni, Pucci, Stefano, Rossi, Oliviero, Salvati, Lorenzo, Schiappoli, Michele, Senna, Gianenrico, Vianello, Andrea, Vultaggio, Alessandra, Baoran, Yang, Incorvaia, Cristoforo, and Canonica, Giorgio Walter

Published
2022
Full Text
View/download PDF

12. Severe asthma: One disease and multiple definitions

Author

Guarnieri, Gabriella, Patella, Vincenzo, Maria Pia, Foschino Barbaro, Carpagnano, Giovanna Elisiana, Colle, Anna del, Scioscia, Giulia, Gerolamo, Pelaia, Puggioni, Francesca, Racca, Francesca, Favero, Elisabetta, Iannacone, Sandra, Savi, Eleonora, Montagni, Marcello, Camiciottoli, Gianna, Allegrini, Chiara, Lombardi, Carlo, Spadaro, Giuseppe, Detoraki, Caterina, Menzella, Francesco, Galeone, Carla, Ruggiero, Patrizia, Yacoub, Monna Rita, Berti, Alvise, Scichilone, Nicola, Durante, Carmen, Costantino, Maria Teresa, Roncallo, Chiara, Braschi, Mariachiara, D’Adda, Alice, Ridolo, Erminia, Triggiani, Massimo, Parente, Roberta, Maria, D’Amato, Verrillo, Maria Vittoria, Rolla, Giovanni, Brussino, Luisa, Frazzetto, Agata Valentina, Cristina, Zappa Maria, Lilli, Marianna, Crimi, Nunzio, Bonavia, Marco, Corsico, Angelo Guido, Grosso, Amelia, Del Giacco, Stefano, Deidda, Margherita, Ricciardi, Luisa, Isola, Stefania, Cicero, Francesca, Amato, Giuliana, Vita, Federica, Spanevello, Antonio, Pignatti, Patrizia, Cherubino, Francesca, Visca, Dina, Massimo Ricciardolo, Fabio Luigi, Anna Carriero, Vitina Maria, Bertolini, Francesca, Santus, Pierachille, Barlassina, Roberta, Airoldi, Andrea, Guida, Giuseppe, Eleonora, Nucera, Aruanno, Arianna, Rizzi, Angela, Caruso, Cristiano, Colantuono, Stefania, Senna, Gianenrico, Caminati, Marco, Arcolaci, Alessandra, Vianello, Andrea, Bianchi, Fulvia Chieco, Marchi, Maria Rita, Centanni, Stefano, Luraschi, Simone, Ruggeri, Silvia, Rinaldo, Rocco, Parazzini, Elena, Calabrese, Cecilia, Flora, Martina, Cosmi, Lorenzo, Di Pietro, Linda, Maggi, Enrico, Pini, Laura, Macchia, Luigi, Di Bona, Danilo, Richeldi, Luca, Condoluci, Carola, Fuso, Leonello, Bonini, Matteo, Farsi, Alessandro, Carli, Giulia, Montuschi, Paolo, Santini, Giuseppe, Conte, Maria Elisabetta, Turchet, Elisa, Barbetta, Carlo, Mazza, Francesco, D’Alo, Simona, Pucci, Stefano, Caiaffa, Maria Filomena, Minenna, Elena, D'Elia, Luciana, Pasculli, Carlo, Viviano, Vittorio, Tarsia, Paolo, Rolo, Joyce, Di Proietto, Mariacarmela, Lo Cicero, Salvatore, Bagnasco, Diego, Paggiaro, Pierluigi, Latorre, Manuela, Folli, Chiara, Testino, Elisa, Bassi, Arianna, Milanese, Manlio, Heffler, Enrico, Manfredi, Andrea, Riccio, Anna Maria, De Ferrari, Laura, Blasi, Francesco, Canevari, Rikki Frank, Canonica, Giorgio Walter, and Passalacqua, Giovanni

Published
2021
Full Text
View/download PDF

14. Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

Author

Guarnieri, Gabriella, Patella, Vincenzo, Maria Pia, Foschino Barbaro, Carpagnano, Elisiana, Colle, Anna del, Scioscia, Giulia, Gerolamo, Pelaia, Paggiaro, Pierluigi, Latorre, Manuela, Puggioni, Francesca, Racca, Francesca, Favero, Elisabetta, Iannacone, Sandra, Savi, Eleonora, Montagni, Marcello, Camiciottoli, Gianna, Allegrini, Chiara, Spadaro, Giuseppe, Detoraki, Caterina, Galeone, Carla, Ruggiero, Patrizia, Yacoub, Monna Rita, Berti, Alvise, Colombo, Gisella, Scichilone, Nicola, Durante, Carmen, Costantino, Maria Teresa, Roncallo, Chiara, Braschi, Mariachiara, Blasi, Francesco, D'Adda, Alice, Ridolo, Erminia, Triggiani, Massimo, Parente, Roberta, Maria, D'Amato, Verrillo, Maria Vittoria, Cristina, Zappa Maria, Lilli, Marianna, Crimi, Nunzio, Bonavia, Marco, Corsico, Angelo Guido, Grosso, Amelia, Del Giacco, Stefano, Deidda, Margherita, Ricciardi, Luisa, Isola, Stefania, Cicero, Francesca, Amato, Giuliana, Vita, Federica, Spanevello, Antonio, Pignatti, Patrizia, Cherubino, Francesca, Visca, Dina, Aletti, Eleonora, Massimo Ricciardolo, Fabio Luigi, Anna Carriero, Vitina Maria, Bertolini, Francesca, Santus, Pierachille, Barlassina, Roberta, Airoldi, Andrea, Guida, Giuseppe, Eleonora, Nucera, Aruanno, Arianna, Rizzi, Angela, Caruso, Cristiano, Colantuono, Stefania, Arcolaci, Alessandra, Vianello, Andrea, Bianchi, Fulvia Chieco, Marchi, Maria Rita, Centanni, Stefano, Luraschi, Simone, Ruggeri, Silvia, Rinaldo, Rocco, Parazzini, Elena, Calabrese, Cecilia, Flora, Martina, Cosmi, Lorenzo, Di Pietro, Linda, Maggi, Enrico, Pini, Laura, Macchia, Luigi, Di Bona, Danilo, Richeldi, Luca, Condoluci, Carola, Fuso, Leonello, Bonini, Matteo, Farsi, Alessandro, Carli, Giulia, Montuschi, Paolo, Santini, Giuseppe, Conte, Maria Elisabetta, Turchet, Elisa, Barbetta, Carlo, Mazza, Francesco, D'Alo, Simona, Pucci, Stefano, Caiaffa, Maria Filomena, Minenna, Elena, D'Elia, Luciana, Pasculli, Carlo, Viviano, Vittorio, Tarsia, Paolo, Rolo, Joyce, Di Proietto, Mariacarmela, Lo Cicero, Salvatore, Bagnasco, Diego, Povero, Massimiliano, Pradelli, Lorenzo, Brussino, Luisa, Rolla, Giovanni, Caminati, Marco, Menzella, Francesco, Heffler, Enrico, Canonica, Giorgio Walter, Senna, Gianenrico, Milanese, Manlio, Lombardi, Carlo, Bucca, Caterina, Manfredi, Andrea, Canevari, Rikki Frank, and Passalacqua, Giovanni

Published
2021
Full Text
View/download PDF

15. The JAK1/JAK2 inhibitor ruxolitinib inhibits mediator release from human basophils and mast cells.

Author

Poto, Remo, Cristinziano, Leonardo, Criscuolo, Gjada, Strisciuglio, Caterina, Palestra, Francesco, Lagnese, Gianluca, Di Salvatore, Antonio, Marone, Gianni, Spadaro, Giuseppe, Loffredo, Stefania, and Varricchi, Gilda

Subjects
MAST cells, CYTOKINE receptors, JAK-STAT pathway, BASOPHILS, RUXOLITINIB, KINASES
Abstract

Introduction: The Janus kinase (JAK) family includes four cytoplasmic tyrosine kinases (JAK1, JAK2, JAK3, and TYK2) constitutively bound to several cytokine receptors. JAKs phosphorylate downstream signal transducers and activators of transcription (STAT). JAK-STAT5 pathways play a critical role in basophil and mast cell activation. Previous studies have demonstrated that inhibitors of JAK-STAT pathway blocked the activation of mast cells and basophils. Methods: In this study, we investigated the in vitro effects of ruxolitinib, a JAK1/2 inhibitor, on IgE- and IL-3-mediated release of mediators from human basophils, as well as substance P-induced mediator release from skin mast cells (HSMCs). Results: Ruxolitinib concentration-dependently inhibited IgE-mediated release of preformed (histamine) and de novo synthesized mediators (leukotriene C4) from human basophils. Ruxolitinib also inhibited anti-IgE- and IL-3-mediated cytokine (IL-4 and IL-13) release from basophils, as well as the secretion of preformed mediators (histamine, tryptase, and chymase) from substance Pactivated HSMCs. Discussion: These results indicate that ruxolitinib, inhibiting the release of several mediators from human basophils and mast cells, is a potential candidate for the treatment of inflammatory disorders. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

Author

Canonica, Giorgio Walter, Blasi, Francesco, Paggiaro, Pierluigi, Senna, Gianenrico, Passalacqua, Giovanni, Spanevello, Antonio, Aliberti, Stefano, Bagnasco, Diego, Bonavia, Marco, Bonini, Matteo, Brussino, Luisa, Bucca, Caterina, Caiaffa, Maria F., Calabrese, Cecilia, Camiciottoli, Gianna, Caminati, Marco, Carpagnano, Giovanna E., Caruso, Cristiano, Centanni, Stefano, Conte, Maria E., Corsico, Angelo G., Cosmi, Lorenzo, Costantino, Maria T., Crimi, Nunzio, D’Alò, Simona, D'Amato, Maria, Del Giacco, Stefano, Farsi, Alessandro, Favero, Elisabetta, Foschino Barbaro, Maria P., Guarnieri, Gabriella, Guida, Giuseppe, Latorre, Manuela, Lo Cicero, Salvatore, Lombardi, Carlo, Macchia, Luigi, Mazza, Francesco, Menzella, Francesco, Milanese, Manlio, Montagni, Marcello, Montuschi, Paolo, Nucera, Eleonora, Parente, Roberta, Patella, Vincenzo, Pelaia, Girolamo, Pini, Laura, Puggioni, Francesca, Ricciardi, Luisa, Ricciardolo, Fabio L.M., Richeldi, Luca, Ridolo, Erminia, Rolla, Giovanni, Santus, Pierachille, Scichilone, Nicola, Spadaro, Giuseppe, Vianello, Andrea, Viviano, Vittorio, Yacoub, Mona R., Zappa, Maria C., and Heffler, Enrico

Published
2020
Full Text
View/download PDF

17. High Prevalence of Long COVID in Common Variable Immunodeficiency:An Italian Multicentric Study

Author

Villa, Annalisa, Milito, Cinzia, Deiana, Carla Maria, Gambier, Renato Finco, Punziano, Alessandra, Buso, Helena, Bez, Patrick, Lagnese, Gianluca, Garzi, Giulia, Costanzo, Giulia, Giannuzzi, Gloria, Pagnozzi, Chiara, Dalm, Virgil A.S.H., Spadaro, Giuseppe, Rattazzi, Marcello, Cinetto, Francesco, Firinu, Davide, Villa, Annalisa, Milito, Cinzia, Deiana, Carla Maria, Gambier, Renato Finco, Punziano, Alessandra, Buso, Helena, Bez, Patrick, Lagnese, Gianluca, Garzi, Giulia, Costanzo, Giulia, Giannuzzi, Gloria, Pagnozzi, Chiara, Dalm, Virgil A.S.H., Spadaro, Giuseppe, Rattazzi, Marcello, Cinetto, Francesco, and Firinu, Davide

Abstract

The long-term effects of SARS-CoV-2 infection represent a relevant global health problem. Long COVID (LC) is defined as a complex of signs and symptoms developed during or after SARS-CoV-2 infection and lasting > 12 weeks. In common variable immunodeficiency (CVID) patients, we previously reported higher risk of hospitalization and death during SARS-CoV-2 infection, as well as prolonged swab positivity and frequent reinfections. The aim of the present study was to assess the risk of LC in an Italian cohort of CVID patients. We used a translated version of the survey proposed by Centers for Disease Control and Prevention (CDC) to collect data on LC. In the enrolled cohort of 175 CVID patients, we found a high prevalence of LC (65.7%). The most frequent LC symptoms were fatigue (75.7%), arthralgia/myalgia (48.7%), and dyspnea (41.7%). The majority of patients (60%) experienced prolonged symptoms, for at least 6 months after infection. In a multivariate analysis, the presence of complicated phenotype (OR 2.44, 95% CI 1.88-5.03; p = 0.015), obesity (OR 11.17, 95% CI 1.37-90.95; p = 0.024), and female sex (OR 2.06, 95% CI 1.09-3.89; p = 0.024) significantly correlated with the development of LC. In conclusion, in this multicenter observational cohort study, we demonstrated that CVID patients present an increased prevalence of LC when compared to the general population. Improved awareness on the risk of LC in CVID patients could optimize management of this new and alarming complication of SARS-CoV-2 infection.

Published
2024

19. Quality of life in patients with allergic and immunologic skin diseases: in the eye of the beholder

Author

Di Agosta, Ester, Salvati, Lorenzo, Corazza, Monica, Baiardini, Ilaria, Ambrogio, Francesca, Angileri, Luisa, Antonelli, Elettra, Belluzzo, Federica, Bonamonte, Domenico, Bonzano, Laura, Brancaccio, Raffaele, Custurone, Paolo, De Marco, Aurora, Detoraki, Aikaterini, Di Guida, Adriana, Di Leo, Elisabetta, Fantò, Marta, Fassio, Filippo, Ferrucci, Silvia Mariel, Foti, Caterina, Gallo, Rosella, Gatta, Alessia, Guarneri, Fabrizio, Guidolin, Lucia, Hansel, Katharina, Lamacchia, Donatella, Lombardo, Carla, Minciullo, Paola Lucia, Napolitano, Maddalena, Pannofino, Alessandro, Paravisi, Andrea, Parente, Roberta, Passante, Maria, Patruno, Cataldo, Peroni, Diego, Quecchia, Cristina, Schettini, Natale, Spadaro, Giuseppe, Stingeni, Luca, Tarrini, Daniele, Tramontana, Marta, Nettis, Eustachio, and Rossi, Oliviero

Published
2021
Full Text
View/download PDF

21. Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry

Author

Aliberti, Stefano, Bagnasco, Diego, Barbuto, Sarah, Camiciottoli, Gianna, Caminati, Marco, Colombo, Giselda, Costantino Maria, Teresa, Crimi, Claudia, Crivellaro, Mariangiola, D'Amato, Mariella, Favero, Elisabetta, Foschino Maria, Pia, Guarnieri, Gabriella, Latorre, Manuela, Lombardi, Carlo, Menzella, Francesco, Patella, Vincenzo, Puggioni, Francesca, Ridolo, Erminia, Rolla, Giovanni, Savi, Eleonora, Scichilone, Nicola, Solidoro, Paolo, Spadaro, Giuseppe, Triggiani, Massimo, Canonica, Giorgio Walter, Colombo, Giorgio Lorenzo, Bruno, Giacomo Matteo, Di Matteo, Sergio, Martinotti, Chiara, Blasi, Francesco, Bucca, Caterina, Crimi, Nunzio, Paggiaro, Pierluigi, Pelaia, Girolamo, Passalaqua, Giovanni, Senna, Gianenrico, and Heffler, Enrico

Published
2019
Full Text
View/download PDF

22. Early Ear, Nose and Throat Manifestations in Eosinophilic Granulomatosis with Poliangioitis: Results from Our Cohort Group and Literature Review

Author

D’Onofrio, Mario, primary, La Prova, Daniele, additional, Galdiero, Maria Rosaria, additional, Cantone, Elena, additional, Tremante, Eugenio, additional, Mascolo, Massimo, additional, Barbieri, Vittoria, additional, Di Nola, Claudio, additional, Spadaro, Giuseppe, additional, de Paulis, Amato, additional, and Detoraki, Aikaterini, additional

Published
2023
Full Text
View/download PDF

23. Decline of gastric cancer mortality in common variable immunodeficiency in the years 2018-2022

Author

Milito, Cinzia, primary, Pulvirenti, Federica, additional, Garzi, Giulia, additional, Sculco, Eleonora, additional, Cinetto, Francesco, additional, Firinu, Davide, additional, Lagnese, Gianluca, additional, Punziano, Alessandra, additional, Discardi, Claudia, additional, Costanzo, Giulia, additional, Felice, Carla, additional, Spadaro, Giuseppe, additional, Ferrari, Simona, additional, and Quinti, Isabella, additional

Published
2023
Full Text
View/download PDF

26. Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis

Author

Portacci, Andrea, primary, Campisi, Raffaele, additional, Buonamico, Enrico, additional, Nolasco, Santi, additional, Pelaia, Corrado, additional, Crimi, Nunzio, additional, Benfante, Alida, additional, Triggiani, Massimo, additional, Spadaro, Giuseppe, additional, Caiaffa, Maria Filomena, additional, Scioscia, Giulia, additional, Detoraki, Aikaterini, additional, Valenti, Giuseppe, additional, Papia, Francesco, additional, Tomasello, Alessandra, additional, Scichilone, Nicola, additional, Pelaia, Girolamo, additional, Crimi, Claudia, additional, and Carpagnano, Giovanna Elisiana, additional

Published
2023
Full Text
View/download PDF

29. Thymic Stromal Lymphopoietin (TSLP) Is Cleaved by Human Mast Cell Tryptase and Chymase.

Author

Canè, Luisa, Poto, Remo, Palestra, Francesco, Iacobucci, Ilaria, Pirozzi, Marinella, Parashuraman, Seetharaman, Ferrara, Anne Lise, Illiano, Amalia, La Rocca, Antonello, Mercadante, Edoardo, Pucci, Piero, Marone, Gianni, Spadaro, Giuseppe, Loffredo, Stefania, Monti, Maria, and Varricchi, Gilda

Subjects
THYMIC stromal lymphopoietin, TRYPTASE, MAST cells, VASCULAR endothelial growth factors, EPITHELIAL cells
Abstract

Thymic stromal lymphopoietin (TSLP), mainly expressed by epithelial cells, plays a central role in asthma. In humans, TSLP exists in two variants: the long form TSLP (lfTSLP) and a shorter TSLP isoform (sfTSLP). Macrophages (HLMs) and mast cells (HLMCs) are in close proximity in the human lung and play key roles in asthma. We evaluated the early proteolytic effects of tryptase and chymase released by HLMCs on TSLP by mass spectrometry. We also investigated whether TSLP and its fragments generated by these enzymes induce angiogenic factor release from HLMs. Mass spectrometry (MS) allowed the identification of TSLP cleavage sites caused by tryptase and chymase. Recombinant human TSLP treated with recombinant tryptase showed the production of 1-97 and 98-132 fragments. Recombinant chymase treatment of TSLP generated two peptides, 1-36 and 37-132. lfTSLP induced the release of VEGF-A, the most potent angiogenic factor, from HLMs. By contrast, the four TSLP fragments generated by tryptase and chymase failed to activate HLMs. Long-term TSLP incubation with furin generated two peptides devoid of activating property on HLMs. These results unveil an intricate interplay between mast cell-derived proteases and TSLP. These findings have potential relevance in understanding novel aspects of asthma pathobiology. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Role of Endothelial G Protein-Coupled Receptor Kinase 2 in Angioedema

Author

Gambardella, Jessica, Sorriento, Daniela, Bova, Maria, Rusciano, Mariarosaria, Loffredo, Stefania, Wang, Xujun, Petraroli, Angelica, Carucci, Laura, Mormile, Ilaria, Oliveti, Marco, Bruno Morelli, Marco, Fiordelisi, Antonella, Spadaro, Giuseppe, Campiglia, Pietro, Sala, Marina, Trimarco, Bruno, Iaccarino, Guido, Santulli, Gaetano, and Ciccarelli, Michele

Published
2020
Full Text
View/download PDF

31. A beacon in the dark: COVID-19 course in CVID patients from two European countries: Different approaches, similar outcomes

Author

Milito, Cinzia, Firinu, Davide, Bez, Patrick, Villa, Annalisa, Punziano, Alessandra, Lagnese, Gianluca, Costanzo, Giulia, van Leeuwen, Leanne P M, Piazza, Beatrice, Deiana, Carla Maria, d'Ippolito, Giancarlo, Del Giacco, Stefano Renato, Rattazzi, Marcello, Spadaro, Giuseppe, Quinti, Isabella, Scarpa, Riccardo, Dalm, Virgil A S H, Cinetto, Francesco, Virology, Internal Medicine, Milito, Cinzia, Firinu, Davide, Bez, Patrick, Villa, Annalisa, Punziano, Alessandra, Lagnese, Gianluca, Costanzo, Giulia, van Leeuwen, Leanne P M, Piazza, Beatrice, Deiana, Carla Maria, D'Ippolito, Giancarlo, Del Giacco, Stefano Renato, Rattazzi, Marcello, Spadaro, Giuseppe, Quinti, Isabella, Scarpa, Riccardo, Dalm, Virgil A S H, and Cinetto, Francesco

Subjects
Common Variable Immunodeficiency (CVID), SDG 3 - Good Health and Well-being, SARS-CoV-2, precision medicine, Immunology, outpatient, Immunology and Allergy, COVID-19, risk factors
Abstract

BackgroundCVID patients present an increased risk of prolonged SARS-CoV-2 infection and re-infection and a higher COVID-19-related morbidity and mortality compared to the general population. Since 2021, different therapeutic and prophylactic strategies have been employed in vulnerable groups (vaccination, SARS-CoV-2 monoclonal antibodies and antivirals). The impact of treatments over the last 2 years has not been explored in international studies considering the emergence of viral variants and different management between countries.MethodsA multicenter retrospective/prospective real-life study comparing the prevalence and outcomes of SARS-CoV-2 infection between a CVID cohort from four Italian Centers (IT-C) and one cohort from the Netherlands (NL-C), recruiting 773 patients.Results329 of 773 CVID patients were found positive for SARS-CoV-2 infection between March 1st, 2020 and September 1st 2022. The proportion of CVID patients infected was comparable in both national sub-cohorts. During all waves, chronic lung disease, “complicated” phenotype, chronic immunosuppressive treatment and cardiovascular comorbidities impacted on hospitalization, whereas risk factors for mortality were older age, chronic lung disease, and bacterial superinfections. IT-C patients were significantly more often treated, both with antivirals and mAbs, than NL-C patients. Outpatient treatment, available only in Italy, started from the Delta wave. Despite this, no significant difference was found for COVID-19 severity between the two cohorts. However, pooling together specific SARS-CoV-2 outpatient treatments (mAbs and antivirals), we found a significant effect on the risk of hospitalization starting from Delta wave. Vaccination with ≥ 3 doses shortened RT-PCR positivity, with an additional effect only in patients receiving antivirals.ConclusionsThe two sub-cohorts had similar COVID-19 outcomes despite different treatment approaches. This points out that specific treatment should now be reserved for selected subgroups of CVID patients, based on pre-existing conditions.

Published
2023

32. BNT162b2 Elicited an Efficient Cell-Mediated Response against SARS-CoV-2 in Kidney Transplant Recipients and Common Variable Immunodeficiency Patients

Author

La Civita, Evelina, primary, Zannella, Carla, additional, Brusa, Stefano, additional, Romano, Paolo, additional, Schettino, Elisa, additional, Salemi, Fabrizio, additional, Carrano, Rosa, additional, Gentile, Luca, additional, Punziano, Alessandra, additional, Lagnese, Gianluca, additional, Spadaro, Giuseppe, additional, Franci, Gianluigi, additional, Galdiero, Massimiliano, additional, Terracciano, Daniela, additional, Portella, Giuseppe, additional, and Loffredo, Stefania, additional

Published
2023
Full Text
View/download PDF

34. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study

Author

Nolasco, Santi, primary, Portacci, Andrea, additional, Campisi, Raffaele, additional, Buonamico, Enrico, additional, Pelaia, Corrado, additional, Benfante, Alida, additional, Triggiani, Massimo, additional, Spadaro, Giuseppe, additional, Caiaffa, Maria Filomena, additional, Scioscia, Giulia, additional, Detoraki, Aikaterini, additional, Valenti, Giuseppe, additional, Papia, Francesco, additional, Tomasello, Alessandra, additional, Crimi, Nunzio, additional, Scichilone, Nicola, additional, Pelaia, Girolamo, additional, Carpagnano, Giovanna Elisiana, additional, and Crimi, Claudia, additional

Published
2023
Full Text
View/download PDF

36. A beacon in the dark:COVID-19 course in CVID patients from two European countries: Different approaches, similar outcomes

Author

Milito, Cinzia, Firinu, Davide, Bez, Patrick, Villa, Annalisa, Punziano, Alessandra, Lagnese, Gianluca, Costanzo, Giulia, van Leeuwen, Leanne P.M., Piazza, Beatrice, Deiana, Carla Maria, d’Ippolito, Giancarlo, Del Giacco, Stefano Renato, Rattazzi, Marcello, Spadaro, Giuseppe, Quinti, Isabella, Scarpa, Riccardo, Dalm, Virgil A.S.H., Cinetto, Francesco, Milito, Cinzia, Firinu, Davide, Bez, Patrick, Villa, Annalisa, Punziano, Alessandra, Lagnese, Gianluca, Costanzo, Giulia, van Leeuwen, Leanne P.M., Piazza, Beatrice, Deiana, Carla Maria, d’Ippolito, Giancarlo, Del Giacco, Stefano Renato, Rattazzi, Marcello, Spadaro, Giuseppe, Quinti, Isabella, Scarpa, Riccardo, Dalm, Virgil A.S.H., and Cinetto, Francesco

Abstract

Background: CVID patients present an increased risk of prolonged SARS-CoV-2 infection and re-infection and a higher COVID-19-related morbidity and mortality compared to the general population. Since 2021, different therapeutic and prophylactic strategies have been employed in vulnerable groups (vaccination, SARS-CoV-2 monoclonal antibodies and antivirals). The impact of treatments over the last 2 years has not been explored in international studies considering the emergence of viral variants and different management between countries. Methods: A multicenter retrospective/prospective real-life study comparing the prevalence and outcomes of SARS-CoV-2 infection between a CVID cohort from four Italian Centers (IT-C) and one cohort from the Netherlands (NL-C), recruiting 773 patients. Results: 329 of 773 CVID patients were found positive for SARS-CoV-2 infection between March 1st, 2020 and September 1st 2022. The proportion of CVID patients infected was comparable in both national sub-cohorts. During all waves, chronic lung disease, “complicated” phenotype, chronic immunosuppressive treatment and cardiovascular comorbidities impacted on hospitalization, whereas risk factors for mortality were older age, chronic lung disease, and bacterial superinfections. IT-C patients were significantly more often treated, both with antivirals and mAbs, than NL-C patients. Outpatient treatment, available only in Italy, started from the Delta wave. Despite this, no significant difference was found for COVID-19 severity between the two cohorts. However, pooling together specific SARS-CoV-2 outpatient treatments (mAbs and antivirals), we found a significant effect on the risk of hospitalization starting from Delta wave. Vaccination with ≥ 3 doses shortened RT-PCR positivity, with an additional effect only in patients receiving antivirals. Conclusions: The two sub-cohorts had similar COVID-19 outcomes despite different treatment approaches. This points out that spe

Published
2023

37. Could it be hereditary angioedema?—Perspectives from different medical specialties

Author

Magerl, Markus, Sala‐Cunill, Anna, Weber‐Chrysochoou, Christina, Trainotti, Susanne, Mormile, Ilaria; https://orcid.org/0000-0001-7599-5426, Spadaro, Giuseppe, Magerl, Markus, Sala‐Cunill, Anna, Weber‐Chrysochoou, Christina, Trainotti, Susanne, Mormile, Ilaria; https://orcid.org/0000-0001-7599-5426, and Spadaro, Giuseppe

Abstract

Hereditary angioedema (HAE) is a rare autosomal dominant disease, with patients often suffering with associated symptoms for many years before receiving a correct diagnosis. The symptoms greatly impact a patient's quality of life (QoL) and include excruciating abdominal pain and angioedema of the skin and submucosa. Angioedema of the larynx represents a significant mortality risk in undiagnosed patients, and a large proportion of patients with HAE receive incorrect diagnoses and undergo unnecessary surgery. HAE‐specific treatments can control and prevent acute life‐threatening episodes, in addition to improving QoL, emphasizing the value of early diagnosis for patients. Diagnostic delay may be due to a lack of HAE awareness by healthcare professionals and the similarity of HAE symptoms with those of more common conditions, complicating differential diagnosis. The multifaceted nature of the condition may result in visits to one of many different medical settings, for example: the Emergency Room, pediatrics, general practice, otolaryngology, gastroenterology, and dermatology. Therefore, it is crucial that physicians in multiple healthcare specialties are aware of the disease to ensure that patients with HAE receive a timely diagnosis. Using patient cases from various medical specialties, this review highlights the necessity for cross‐specialty awareness of HAE and outlines the essential information for the various healthcare professionals that may encounter a patient with HAE symptoms, in order to effectively treat and/or diagnose HAE.

Published
2023

38. Early Ear, Nose and Throat Manifestations in Eosinophilic Granulomatosis with Poliangioitis: Results from Our Cohort Group and Literature Review.

Author

D'Onofrio, Mario, La Prova, Daniele, Galdiero, Maria Rosaria, Cantone, Elena, Tremante, Eugenio, Mascolo, Massimo, Barbieri, Vittoria, Di Nola, Claudio, Spadaro, Giuseppe, de Paulis, Amato, and Detoraki, Aikaterini

Subjects
LITERATURE reviews, NASAL polyps, CHURG-Strauss syndrome, NASAL bone, SYMPTOMS, HEARING disorders
Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, systemic necrotizing vasculitis affecting small-to-medium-sized vessels. EGPA's clinical manifestations are heterogeneous, affecting different organs and systems, and the upper respiratory tract can be affected by ear, nose and throat (ENT) involvement. The aim of our study was to assess type manifestations at the time of diagnosis in a cohort of EGPA patients and correlate findings with baseline variables (sex, age, antineutrophil cytoplasmic antibodies—ANCA-status) and literature reports. The main ENT manifestations in our patients at the time of diagnosis were: chronic rhinosinusitis with nasal polyposis (CRSwNP) (52%), turbinate hypertrophy (48%), nasal swelling (40%), rhinorrhea (40%), chronic rhinosinusitis without nasal polyposis (CRSsNP) (32%), nasal bone deformities (32%), nasal crusts (20%), nasal mucosal ulcers (12%), corditis (12%), hoarseness/dysphonia (12%), hearing loss (12%), mucoceles (4%) and eosinophilic rhinitis (4%). No correlations were found between sex, age, ANCA status and ENT clinical manifestations. A polymorphic ENT involvement is often observed in the early stages of EGPA. The presence of nasal, sinus, ear and/or laryngeal manifestations in patients with asthma and hypereosinophilia, independently of sex, age or ANCA status, should raise an alert for further investigation and differential diagnosis for EGPA. ENT specialists should be aware of their leading position in this diagnostic race. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. Exhaled Nitric Oxide as Biomarker of Type 2 Diseases.

Author

Maniscalco, Mauro, Fuschillo, Salvatore, Mormile, Ilaria, Detoraki, Aikaterini, Sarnelli, Giovanni, Paulis, Amato de, Spadaro, Giuseppe, and Cantone, Elena

Subjects
NITRIC oxide, EOSINOPHILIC esophagitis, ALLERGIC rhinitis, ATOPIC dermatitis, FOOD allergy, CELLULAR aging
Abstract

Nitric oxide (NO) is a short-lived gas molecule which has been studied for its role as a signaling molecule in the vasculature and later, in a broader view, as a cellular messenger in many other biological processes such as immunity and inflammation, cell survival, apoptosis, and aging. Fractional exhaled nitric oxide (FeNO) is a convenient, easy-to-obtain, and non-invasive method for assessing active, mainly Th2-driven, airway inflammation, which is sensitive to treatment with standard anti-inflammatory therapy. Consequently, FeNO serves as a valued tool to aid the diagnosis and monitoring of several asthma phenotypes. More recently, FeNO has been evaluated in several other respiratory and/or immunological conditions, including allergic rhinitis, chronic rhinosinusitis with/without nasal polyps, atopic dermatitis, eosinophilic esophagitis, and food allergy. In this review, we aim to provide an extensive overview of the current state of knowledge about FeNO as a biomarker in type 2 inflammation, outlining past and recent data on the application of its measurement in patients affected by a broad variety of atopic/allergic disorders. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Multicentric Observational Study on Safety and Tolerability of COVID-19 Vaccines in Patients with Angioedema with C1 Inhibitor Deficiency: Data from Italian Network on Hereditary and Acquired Angioedema (ITACA)

Author

Parente, Roberta, primary, Sartorio, Silvio, additional, Brussino, Luisa, additional, De Pasquale, Tiziana, additional, Zoli, Alessandra, additional, Agolini, Stefano, additional, Di Agosta, Ester, additional, Quattrocchi, Paolina, additional, Borrelli, Paolo, additional, Bignardi, Donatella, additional, Petraroli, Angelica, additional, Senter, Riccardo, additional, Popescu Janu, Valentina, additional, Cogliati, Chiara, additional, Guarino, Maria Domenica, additional, Rossi, Oliviero, additional, Firinu, Davide, additional, Pucci, Stefano, additional, Spadaro, Giuseppe, additional, Triggiani, Massimo, additional, Cancian, Mauro, additional, and Zanichelli, Andrea, additional

Published
2023
Full Text
View/download PDF

41. Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry

Author

Giorgio Walter Canonica, Giorgio Lorenzo Colombo, Giacomo Matteo Bruno, Sergio Di Matteo, Chiara Martinotti, Francesco Blasi, Caterina Bucca, Nunzio Crimi, Pierluigi Paggiaro, Girolamo Pelaia, Giovanni Passalaqua, Gianenrico Senna, Enrico Heffler, Aliberti Stefano, Bagnasco Diego, Barbuto Sarah, Camiciottoli Gianna, Caminati Marco, Colombo Giselda, Costantino Maria Teresa, Crimi Claudia, Crivellaro Mariangiola, D'Amato Mariella, Favero Elisabetta, Foschino Maria Pia, Guarnieri Gabriella, Latorre Manuela, Lombardi Carlo, Francesco Menzella, Patella Vincenzo, Puggioni Francesca, Ridolo Erminia, Rolla Giovanni, Savi Eleonora, Scichilone Nicola, Solidoro Paolo, Spadaro Giuseppe, and Triggiani Massimo

Subjects
Immunologic diseases. Allergy, RC581-607
Abstract

Background: Asthma is one of the most common non-communicable respiratory diseases, affecting about 6% of the general population. Severe asthma, even if afflicts a minority of asthmatics, drives the majority of costs of the disease. The aim of this study is to create a pharmacoeconomic model to predict the costs of corticosteroid-related adverse events in severe asthmatics and applying it to the first published epidemiologic data from the Severe Asthma Network in Italy (SANI) registry. Methods: The analysis was conducted from the perspective of the Italian National Healthcare System (INHS). Model inputs, derived from literature, included: asthma epidemiology data, frequency of adverse events, percentage of severe asthma treated with OCS and adverse event cost (Diagnosis-Related Group (DRG) national tariffs). We estimated costs per different patient groups: non-asthma controls, mild/moderate and severe asthmatics. Final results report estimated direct cost per patient and total direct cost for overall target population, showing economic impact related to corticosteroid complication. Results: Based on epidemiological data input, in Italy, asthmatic subjects resulted about 3,999,600, of which 199,980 with severe asthma. The number of patients with severe asthma OCS-treated was estimated at 123,988. Compared to the non-asthma control cohort and to that with moderate asthma annual cost per severe asthmatic patient resulted respectively about €892 and €606 higher, showing a corticosteroids shadow cost ranging from 45% to 30%.Applying the cost per patient to the target population identified for Italy, the budget impact model estimated a total annual cost related to OCS-related adverse events of €242.7 million for severe asthmatics. In respect with non-asthmatic and moderate population, an incremental expenditure of about € 110.6 million and €75.2, respectively, were shown. Conclusions: Our study provides the first estimates of additional healthcare costs related to corticosteroid induced adverse events in severe asthma patient. Budget impact model results highlighted the relevant economic impact of OCS-related adverse events in severe asthma patients. The future extrapolation of additional data from SANI registry will support the development of a model to investigate the role of corticosteroids sparing drugs. Keywords: Severe asthma, Oral corticosteroids, Adverse events, Pharmacoeconomy, Costs, Diabetes, Glaucoma, Obesity, Bone fracture, Chronic kidney disease

Published
2019
Full Text
View/download PDF

43. Epigenetics: An opportunity to shape innate and adaptive immune responses

Author

Liotti, Antonietta, primary, Ferrara, Anne Lise, additional, Loffredo, Stefania, additional, Galdiero, Maria Rosaria, additional, Varricchi, Gilda, additional, Di Rella, Francesca, additional, Maniscalco, Giorgia Teresa, additional, Belardo, Martina, additional, Vastano, Roberta, additional, Prencipe, Rosaria, additional, Pignata, Laura, additional, Romano, Roberta, additional, Spadaro, Giuseppe, additional, de Candia, Paola, additional, Pezone, Antonio, additional, and De Rosa, Veronica, additional

Published
2022
Full Text
View/download PDF

44. A Multidisciplinary Approach for Type 2 Allergic Diseases: What Do Biologics Teach Us?

Author

Maniscalco, Mauro, Detoraki, Aikaterini, Sarnelli, Giovanni, Nolano, Maria, De Paulis, Amato, Spadaro, Giuseppe, and Cantone, Elena

Subjects
ALLERGIES, IMMUNOGLOBULIN E, THYMIC stromal lymphopoietin, ATOPIC dermatitis, MONOCLONAL antibodies, TH2 cells
Abstract

In line with a growing body of evidence, if some Th2-driven pathophysiological mechanisms are shared across multiple atopic/allergic disorders, it is possible to hypothesize that, by treating a single clinical condition in an individual with multiple Th2 diseases, a simultaneous improvement can be obtained. Patients with atopic/allergic disorders, including atopic dermatitis (AD), allergic rhino-conjunctivitis (AR), chronic rhinosinusitis with/without nasal polyps (CRSwNP/CRSsNP), bronchial asthma, food allergy, and eosinophilic esophagitis (EoE), often share a common genetic background, a type Th2 polarized immune response, and several environmental factors [[1]]. However, although the positive clinical response to biologics confirms the association between Th2-driven diseases, no biomarker with high specificity can anticipate the therapeutic response in either single or multiple Th2 conditions. The presence of several allergic disorders in the same individuals suggests that some subgroups of allergic diseases share the same subtype of health condition, namely the "endotype" variety, especially the Th2-driven endotype. [Extracted from the article]

Published
2023
Full Text
View/download PDF

45. Real-life data on monoclonal antibodies and antiviral drugs in Italian inborn errors of immunity patients during COVID-19 pandemic

Author

Garzi, Giulia, primary, Cinetto, Francesco, additional, Firinu, Davide, additional, Di Napoli, Giulia, additional, Lagnese, Gianluca, additional, Punziano, Alessandra, additional, Bez, Patrick, additional, Cinicola, Bianca Laura, additional, Costanzo, Giulia, additional, Scarpa, Riccardo, additional, Pulvirenti, Federica, additional, Rattazzi, Marcello, additional, Spadaro, Giuseppe, additional, Quinti, Isabella, additional, and Milito, Cinzia, additional

Published
2022
Full Text
View/download PDF

46. Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy

Author

Milito, Cinzia, primary, Cinetto, Francesco, additional, Palladino, Andrea, additional, Garzi, Giulia, additional, Punziano, Alessandra, additional, Lagnese, Gianluca, additional, Scarpa, Riccardo, additional, Rattazzi, Marcello, additional, Pesce, Anna Maria, additional, Pulvirenti, Federica, additional, Di Napoli, Giulia, additional, Spadaro, Giuseppe, additional, Carsetti, Rita, additional, and Quinti, Isabella, additional

Published
2022
Full Text
View/download PDF

47. Gender dimorphism in IgA subclasses in T2-high asthma

Author

Varricchi, Gilda, primary, Poto, Remo, additional, Covelli, Bianca, additional, Di Spigna, Gaetano, additional, Galdiero, Maria Rosaria, additional, Marone, Gianni, additional, Postiglione, Loredana, additional, and Spadaro, Giuseppe, additional

Published
2022
Full Text
View/download PDF

48. Macrophage-polarizing stimuli differentially modulate the inflammatory profile induced by the secreted phospholipase A2 group IA in human lung macrophages. GALDIERO AND FERRARA ARE CO-FIRST AUTHORS

Author

Ferrara, Anne Lise, Galdiero, Maria Rosaria, Fiorelli, Alfonso, Cristinziano, Leonardo, Granata, Francescopaolo, Marone, Giancarlo, Crescenzo, Rosa Maria Di, Braile, Mariantonia, Marcella, Simone, Modestino, Luca, Varricchi, Gilda, Spadaro, Giuseppe, Santini, Mario, Loffredo, Stefania, Ferrara, Anne Lise, Galdiero, Maria Rosaria, Fiorelli, Alfonso, Cristinziano, Leonardo, Granata, Francescopaolo, Marone, Giancarlo, Crescenzo, Rosa Maria Di, Braile, Mariantonia, Marcella, Simone, Modestino, Luca, Varricchi, Gilda, Spadaro, Giuseppe, Santini, Mario, and Loffredo, Stefania

Subjects
Inflammation, Angiogenesi, Macrophage polarization, Secretory phospholipases A(2)
Abstract

In this study we investigated the effects of snake venom Group IA secreted phospholipase A2 (svGIA) on the release of inflammatory and angiogenic mediators from human lung macrophages (HLMs). HLMs were incubated with lipopolysaccharide (LPS) or svGIA with or without macrophage-polarizing stimuli (IL-4, IL-10, IFN-γ or the adenosine analogue NECA). M2-polarizing cytokines (IL-4 and IL-10) inhibited TNF-α, IL-6, IL-12, IL-1β, CXCL8 and CCL1 release induced by both LPS and svGIA. IL-4 inhibited also the release of IL-10. IFN-γ reduced IL-10 and IL-12 and increased CCL1 release by both the LPS and svGIA-stimulated HLMs, conversely IFN-γ reduced IL-1β only by svGIA-stimulated HLMs. In addition, IFNγ promoted TNF-α and IL-6 release from svGIA-stimulated HLMs to a greater extent than LPS. NECA inhibited TNF-α and IL-12 but promoted IL-10 release from LPS-stimulated HLMs according to the well-known effect of adenosine in down-regulating M1 activation. By contrast NECA reduced TNF-α, IL-10, CCL1 and IL-1β release from svGIA-activated HLM. IL-10 and NECA increased both LPS- and svGIA-induced vascular endothelial growth factor A (VEGF-A) release. By contrast, IL-10 reduced angiopoietin-1 (ANGPT1) production from activated HLMs. IFN-γ and IL-4 reduced VEGF-A and ANGPT1 release from both LPS- and svGIA-activated HLMs. Moreover, IL-10 inhibited LPS-induced ANGPT2 production. In conclusion, we demonstrated a fine-tuning modulation of svGIA-activated HLMs differentially exerted by the classical macrophage-polarizing cytokines.

Published
2021

50. Severe asthma: One disease and multiple definitions

Author

Bagnasco, Diego, primary, Paggiaro, Pierluigi, additional, Latorre, Manuela, additional, Folli, Chiara, additional, Testino, Elisa, additional, Bassi, Arianna, additional, Milanese, Manlio, additional, Heffler, Enrico, additional, Manfredi, Andrea, additional, Riccio, Anna Maria, additional, De Ferrari, Laura, additional, Blasi, Francesco, additional, Canevari, Rikki Frank, additional, Canonica, Giorgio Walter, additional, Passalacqua, Giovanni, additional, Guarnieri, Gabriella, additional, Patella, Vincenzo, additional, Maria Pia, Foschino Barbaro, additional, Carpagnano, Giovanna Elisiana, additional, Colle, Anna del, additional, Scioscia, Giulia, additional, Gerolamo, Pelaia, additional, Puggioni, Francesca, additional, Racca, Francesca, additional, Favero, Elisabetta, additional, Iannacone, Sandra, additional, Savi, Eleonora, additional, Montagni, Marcello, additional, Camiciottoli, Gianna, additional, Allegrini, Chiara, additional, Lombardi, Carlo, additional, Spadaro, Giuseppe, additional, Detoraki, Caterina, additional, Menzella, Francesco, additional, Galeone, Carla, additional, Ruggiero, Patrizia, additional, Yacoub, Monna Rita, additional, Berti, Alvise, additional, Scichilone, Nicola, additional, Durante, Carmen, additional, Costantino, Maria Teresa, additional, Roncallo, Chiara, additional, Braschi, Mariachiara, additional, D’Adda, Alice, additional, Ridolo, Erminia, additional, Triggiani, Massimo, additional, Parente, Roberta, additional, Maria, D’Amato, additional, Verrillo, Maria Vittoria, additional, Rolla, Giovanni, additional, Brussino, Luisa, additional, Frazzetto, Agata Valentina, additional, Cristina, Zappa Maria, additional, Lilli, Marianna, additional, Crimi, Nunzio, additional, Bonavia, Marco, additional, Corsico, Angelo Guido, additional, Grosso, Amelia, additional, Del Giacco, Stefano, additional, Deidda, Margherita, additional, Ricciardi, Luisa, additional, Isola, Stefania, additional, Cicero, Francesca, additional, Amato, Giuliana, additional, Vita, Federica, additional, Spanevello, Antonio, additional, Pignatti, Patrizia, additional, Cherubino, Francesca, additional, Visca, Dina, additional, Massimo Ricciardolo, Fabio Luigi, additional, Anna Carriero, Vitina Maria, additional, Bertolini, Francesca, additional, Santus, Pierachille, additional, Barlassina, Roberta, additional, Airoldi, Andrea, additional, Guida, Giuseppe, additional, Eleonora, Nucera, additional, Aruanno, Arianna, additional, Rizzi, Angela, additional, Caruso, Cristiano, additional, Colantuono, Stefania, additional, Senna, Gianenrico, additional, Caminati, Marco, additional, Arcolaci, Alessandra, additional, Vianello, Andrea, additional, Bianchi, Fulvia Chieco, additional, Marchi, Maria Rita, additional, Centanni, Stefano, additional, Luraschi, Simone, additional, Ruggeri, Silvia, additional, Rinaldo, Rocco, additional, Parazzini, Elena, additional, Calabrese, Cecilia, additional, Flora, Martina, additional, Cosmi, Lorenzo, additional, Di Pietro, Linda, additional, Maggi, Enrico, additional, Pini, Laura, additional, Macchia, Luigi, additional, Di Bona, Danilo, additional, Richeldi, Luca, additional, Condoluci, Carola, additional, Fuso, Leonello, additional, Bonini, Matteo, additional, Farsi, Alessandro, additional, Carli, Giulia, additional, Montuschi, Paolo, additional, Santini, Giuseppe, additional, Conte, Maria Elisabetta, additional, Turchet, Elisa, additional, Barbetta, Carlo, additional, Mazza, Francesco, additional, D’Alo, Simona, additional, Pucci, Stefano, additional, Caiaffa, Maria Filomena, additional, Minenna, Elena, additional, D'Elia, Luciana, additional, Pasculli, Carlo, additional, Viviano, Vittorio, additional, Tarsia, Paolo, additional, Rolo, Joyce, additional, Di Proietto, Mariacarmela, additional, and Lo Cicero, Salvatore, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results